MAZE THERAPEUTICS, INC. COMMON STOCK
NASDAQ: MAZE (Maze Therapeutics, Inc.)
Kemas kini terakhir: 16 jam lalu11.50
-0.36 (-3.04%)
| Penutupan Terdahulu | 11.86 |
| Buka | 12.15 |
| Jumlah Dagangan | 78,157 |
| Purata Dagangan (3B) | 149,557 |
| Modal Pasaran | 503,667,808 |
| Harga / Pendapatan (P/E TTM) | 164.29 |
| Harga / Jualan (P/S) | 3.17 |
| Harga / Buku (P/B) | 1.82 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 May 2025 |
| Margin Keuntungan | 31.01% |
| Margin Operasi (TTM) | 29.97% |
| EPS Cair (TTM) | 0.070 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.84% |
| Nisbah Semasa (MRQ) | 16.10 |
| Aliran Tunai Operasi (OCF TTM) | 69.88 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 52.09 M |
| Pulangan Atas Aset (ROA TTM) | 23.07% |
| Pulangan Atas Ekuiti (ROE TTM) | 34.38% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Maze Therapeutics, Inc. | Menurun | - |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | -0.25 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 5.91% |
| % Dimiliki oleh Institusi | 92.17% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Matrix Capital Management Company, Lp | 31 Mar 2025 | 2,486,184 |
| Foresite Capital Management Iv, Llc | 31 Mar 2025 | 2,111,919 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 May 2025 | Pengumuman | Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference |
| 14 May 2025 | Pengumuman | Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones |
| 13 May 2025 | Pengumuman | Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |